Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00917579 · ClinicalTrials.gov registry record · Phase 4
Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
A Phase 4 study of Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00917579 is a Phase 4 study of Hypercholesterolemia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 76 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00917579, a Phase 4 study of Hypercholesterolemia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
• To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (1)
Florida
- Pfizer Investigational Site - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00917579
The ClinicalTrials.gov registry entry for NCT00917579 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (91% lower). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00917579 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00917579 about?
NCT00917579 is a clinical study titled "Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet". • To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
What is the current status of trial NCT00917579?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2008-07. Estimated completion is 2008-09.
What conditions does trial NCT00917579 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT00917579?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00917579?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00917579 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
COMPLETED · Phase 4
-
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
COMPLETED · Phase 4
-
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
COMPLETED · Phase 4
-
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
COMPLETED · Phase 4
-
Cholesterol and Pharmacogenetic Study
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.